Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3791932 A
Publication typeGrant
Publication date12 Feb 1974
Filing date27 Jan 1972
Priority date10 Feb 1971
Also published asCA958314A1, CA1040082B, DE2206103A1, DE2206103B2
Publication numberUS 3791932 A, US 3791932A, US-A-3791932, US3791932 A, US3791932A
InventorsA Schuurs, B Weemen
Original AssigneeAkzona Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Process for the demonstration and determination of reaction components having specific binding affinity for each other
US 3791932 A
Abstract
The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.
Images(8)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [191 Schuurs et al.

[451 Feb. 12, 1974 [75] Inventors: Antonius Hermanus Wilhelmus Maria Schuurs; Bauke Klaas Van Weemen, both of Oss, Netherlands [73] Assignee: Akzona Incorporated, Asheville,

22 Filed: Jan. 27, 1972 21 App]. No.: 221,447

[30] Foreign Application Priority Data Feb. 10, 1971 Netherlands 7101728 [52] US. Cl. 195/l03.5 R, 424/12, 23/230 B [51] Int. Cl. G0ln 31/14 [58] Field of Search 195/103.5 R; 23/230 B; 424/12 [56] References Cited UNITED STATES PATENTS 3,654,090 4/1972 Schuurs et al. 195/1035 R Primary Examiner-Alvin E. Tanenholtz Assistant ExaminerMax D. Hensley Attorney, Agent, or Firm--Hugo E. Weisberger [57] ABSTRACT The present invention relates to a process for the determination of a component of the reaction between a specific binding protein and the substance being specifically bound by such a protein comprising reacting the component to be determined with its binding partner in an insolubilized form, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a determined amount of a coupling product of the substance to be determined with an enzyme, and finally determining the enzyme activity of the liquid or solid phase of the reaction mixture obtained.

4 Claims, N0 Drawings PROCESS FOR THE DEMONSTRATION AND DETERMINATION OF REACTION COMPONENTS HAVING SPECIFIC BINDING AFFINITY FOR EACH OTHER For the demonstration and determination of substances playing a prominent part in biochemical processes, i.e. low molecular substances, such as vitamins and steroids, or high molecular ones, such as proteins and carbohydrates, it is often possible to employ reactions of these substances with proteins having a specific binding affinity for these substances. Thus, it is possible to determine the concentration of a steroid by employing a protein capable of binding this steroid specifically. As examples of such combinations are mentioned cortisol and transcortin, l7B-oestradiol and the oestradiol-binding receptor protein of the uterus.

It is also possible to link a low molecular substance chemically with a protein, and to inject this conjugate into a test animal, which then reacts by forming antibodies against, among others, the low molecular substance. The latter is in this case to be regarded as a socalled hapten. The antibodies against the hapten may be regarded as a special case of specific binding proteins.

High molecular substances, such as simple and conjugated proteins and carbohydrates, are capable of causing the formation of antibodies on being injected into animals in the correct experimental conditions. Between these antibodies and the injected high molecular substance, the antigen, there is again question of specific binding affinity.

Determination methods in which these specific binding affinities are employed, are often based on the competition between the substance to be determined in the sample and the known quantity of the same substance, labelled radioactive, for a limited quantity of its binding partner. The quantity of substance to be determined determines what part of the radioactive labelled substance can be bound by its binding partner. It is also possible to determine an unknown quantity of specific binding protein by reacting a sample of it with a certain quantity of radioactive labelled, specific binding substance. The terms by which these methods are designated in the literature, depend upon the nature of the specific binding protein. They speak of competitive protein binding assays, where receptor or transport proteins are used, and of"radioimmunological determinations" where antibodies are employed as specificbinding protein.

Instead of labelling one of the components of the above-described reactions with a radioactive isotope, it is also possible to employ an enzyme as a labelling substance. Where use is made of the binding affinity between a low molecular substance and its specif c binding protein, the low molecular substance can be coupled with an enzyme. The coupling product, low molecular substance/enzyme, can then be used in experimental set-ups as described above. Where use is made of the binding affinity between an antigen and its antibody, the antigen may, for example, be coupled with an enzyme instead of labelling it with a radioactive isotope as is conventional in radioimmunological methods.

For all the methods in which such a labelled reaction component is employed, a suitable method for separating the free labelled compound attached to the binding partner, is essential. Dependent upon the nature of the substances participating in the reaction, various separation methods can be employed, for example electrophoresis, gel filtration, selective adsorption, application of one of the reaction components in an insolubilised form, and application of antibodies against one of the reaction components, also in an insolubilised form.

In spite of the high sensitivity that can be achieved by these methods, it is not always possible to demonstrate or determine substances occurring in extremely low concentrations in, for example, serum or urine. Thus, it is very difficult and often impossible to demonstrate adrenocorticotrophic hormone (ACTH) by a radioimmunological method, unless one has the disposal of a very rare antiserum containing antisubstances with an extremely high binding affinity for ACTH.

Also determinations of smaller peptide hormones such as oxytocin in non-extracted serum, causes great difficulties, because the required sensitivity cannot be reached.

Although, in principle, the immunological crossreaction between HCG and LH enables both hormones to be determined with one test-system, most methods for the determination of human chorionic gonadotrophin (HCG) by a coupling product of HCG and an enzyme cannot be used for the demonstration and determination of luteinizing hormone (LH). This is due to the fact that LH occurs in much lower concentrations in blood and urine than HCG during pregnancy, so that the sensitivity of the test systems are insufficient. This shortage of sensitivity can be decreased by extracting the substance to be determined from the medium in which it occurs or by concentrating the medium. These methods, however, are very laborious, and the results often unsatisfactory.

A process has now been found for the demonstration and determination of a component of the reaction between specific binding proteins and the substances that can be specifically bound by these proteins, using the known binding affinity of such components for each other, which comprises reacting the component to be determined with its binding partner, which has been or is insolubilised, separating the solid phase of the reaction mixture from the liquid phase, reacting the solid phase with a coupling product, obtained by binding a substance capable of reacting specifically with one of the reaction components, to an enzyme, and finally determining the enzyme activity of the liquid or the solid phase in the reaction mixture obtained, which is a measure for the quantity of the substance to be determined.

The binding partner required for the determination of the component present in an unknown quantity, is employed in an insoluble form. The determination can take place by adding the binding partner to the reaction mixture in an insoluble form and reacting the mixture in a heterogeneous medium, but the binding partner can also be added in a dissolved form, after which it can be insolubilised by adding antisubstances against it.

The substance capable of reacting specifically with one of the reaction components, and which is employed coupled with an enzyme, may be the other reaction component, but also a third substance that must possess a specific affinity for one of the components of the reaction.

The method can be applied to the various reaction systems described above, i.e. antigen/antibody, hapten- /antibody and a low molecular substance/specific binding protein. As third substance a second antibody may occur, that is to say, an antibody against the gammaglobulin fraction of the species of animal in which the first antibodies have been generated. This situation may occur in the systems antigen/(first) antibody and hapten/(first) antibody. As third substance may also occur an antibody against a specific binding protein.

The essence of the method is the performance in two steps, in between which a separation takes place of the liquid and the solid phase of the reaction mixture. With the solid phase the second step is performed. Only in this stage the enzyme coupling product is employed and the enzyme activity determined.

The most important advantages of the method found are:

l. the first step can be performed in a larger volume than is desirable or possible for the second step. This is of great importance when the substance to be determined occurs in too low concentrations to be determined by known methods.

2. In the liquid to be examined substances may be present influencing the reactions in the second step unfavourably. Especially the enzyme present in the coupling product and the enzymatic catalysing reaction may be sensitive to disturbing substances in the test liquid.

The method found can especially be employed for the determination of substances present in body liquids such as hormones, their antibodies and specific binding proteins, as well as enzymes. Also factors of bloodclotting, fibrinolysis and complement systems, pathological proteins in body liquids, as well as antibodies against pathogenic microorganisms and iso-antibodies can be determined in this manner.

The medium in which the first step of the determination takes place often consists for a large part of test liquid, such as urine or serum. If considered necessary, it can be adjusted to the pH required for the immunochemical reaction, viz. between 5 and 9, by adding a dry buffer salt or a small volume of a concentrated buffer solution. The medium of the second step is also a buffer of a pH required for the immunochemical reaction. For this purpose phosphate buffers, citrate buffers, tris(hydroxy methyl)-aminomethane, and imidazole buffers can be employed. It may be necessary to use for the relative enzyme reaction a buffer of another composition and pH, which depends upon the enzyme employed.

The manufacture of the insolubilised reaction component can take place in various manners, i.a. dependent upon the properties of this reaction component. Thus, antibodies, specific binding proteins and proteinlike antigen can be insolubilised by cross-linking, for example, glutaric aldehyde and chloroformic acid ethyl ester, by physical adsorption or chemical coupling with an insoluble carrier, such as cellulose compounds, agarose, cross-linked dextran, polystyrene and the like, or by coupling with antibodies against the relative protein coupled with an insoluble carrier. Low molecular substances can be bound by methods dependent upon the structure of the low molecular substance and the carrier material. Some of the low molecular substances may already possess groups capable of reacting with the reactive parts on the carrier material: in other cases such groups will have to be introduced by organic chemical reactions.

The manufacture of the enzyme coupling products is also performed by methods dependent upon the properties of the molecules incorporated into the coupling product. A covalent bond of proteins to enzymes can be effected by reagents such as carbodiimides, diisocyanates, glutaric aldehyde and bis-diazobenzidine. The coupling of low molecular substances can take place in various manners. Some of these substances may already possess groups that can be cross-linked with reactive groups of the enzyme; in other cases such groups will have to be introduced by organic chemical reactions. It stands to reason that in the manufacture of these coupling products the original binding properties of the substances bound to the enzyme may not change very much; no more may the enzyme activity be decreased considerably.

The choice of the enzyme that is to form a part of the coupling product, is determined by properties such as the specific binding activity (a high conversion rate raises the sensitivity of the test system) and the simplicity of the determination of the enzyme. The determination of an enzyme catalysing a conversion in which coloured reaction components are involved, is simple. Such colorimetric determinations can be automated in a simple manner.

According to the invention it is also possible to employ enzymes catalysing those conversions in which reaction components are involved that can be determined spectrophotometrically or fluorimetrically. These determinations can also be automated.

In the manufacture of the coupling products enzymes such as catalase, peroxidase, B-glucuronidase, B-B- glucosidase, ,B-D-galactosidase, urease, glucoseoxidase and galactose-oxidase are preferred, especially the group of the oxidoreductases.

The determinations according to the invention are broadly performed as follows: A certain volume of a test liquid, for example 10 ml, containing a very low concentration of the component to be determined, is mixed with a certain quantity of an insolubilised reaction partner of the substance to be determined. The test liquid may be urine, in which the component to be determined occurs in low concentration, or serum, which has been diluted to diminish the influence of disturbing factors. In order to enable the reaction to be performed in the heterogeneous system, the mixture is agitated. The resulting solid phase is separated from the test liquid, for example by centrifugation, and washed, if considered necessary. The first part of the determination can also be performed by incubating the test liquid with a certain quantity of the reaction partner of the substance to be determined in a dissolved form, after which a quantity of insolubilised antibody against that reaction partner is added and the mixture agitated and finally centrifuged. Separation by filtration and decantation is also possible.

The second part of the determination is performed by resuspending the insoluble substance, which forms the The enzyme activity of a phase of the reaction mixture is demonstrated or measured by incubating that phase with a substrate and other substances required for the relative enzyme reaction.

Preferably a reaction is employed in which a coloured compound is formed, or removed, whose adsorption can be easily quantitatively determined.

The form in which the reagents can be used are manifold. The component of the reaction system coupled with an enzyme may have been dissolved in a buffer, or freeze-dried. Also a solid carrier can be used, for example a strip of paper impregnated with the enzyme coupling product.

The insoluble component can be processed in the form of particles of various sizes, such as grains, plates and rods, or in the form of a strip of some or other carrier material.

For the performance of the process according to the invention a test-pack is usually employed, chiefly consisting of:

a. a certain quantity of the enzyme coupling product;

b. a corresponding quantity of one of the components of the reaction system in an insoluble form;

c. a substrate for the determination of the quantity of the enzyme employed.

The test-pack can contain the necessary auxiliaries, if required, to make a dilution series of the sample to be tested for a quantitative determination, such as test tubes, pipettes and flasks containing a diluent. For the determination of antigens or haptens, or their antibodies, the test-pack contains at least:

a. a certain quantity of the coupling product of the antigen or hapten, or an antibody against it, and an enzyme;

b. a corresponding quantity of an insolubilised component of the reaction system antigen/antibody, or hapten/antibody, and

c. a substrate for the determination of the enzyme activity.

The invention is further illustrated by the following examples, which are on no account intended to limit the invention.

EXAMPLE I Determination of human chorionic gonadotrophin (HCG) in serum.

a. Preparation of HCG-HRP. Five mg of HCG and 20 mg of horse-radish peroxidase (HRP) were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.2. After 40 u/ltr of 25 percent glutaric aldehyde solution had been added, the mixture was shaken at room temperature for 2 hours. Then the mixture was centrifuged for 5 minutes at 250 g, after which it was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.2. The fractions whose highest percentage of enzyme activity was bound by antibodies against HCG, were used in the test system.

b. Preparation of antibodies against HCG. Antibodies against HCG were generated in rabbits as described by Schuurs et. al. in Acta Endocr. (Kbh.) 59, (1968).

c. Preparation of the immuno-adsorbent, anti-HCG- cellulose. The y-globulin fraction of the anti-HCG- serum described under 1)) was prepared by precipitation with 18 percent (w/v) solid Na SO The precipitate was washed and then taken up in so much 0.05 M borate buffer of pH 8.6 that the ultimate protein concentration was 10 mg/ml. M-aminobenzyloxy methyl cellulose (350 mg) prepared by Gurvichs method, described in Biokhimiya 26, 934 (1961 was suspended in 50 ml of distilled water and diazotized by adding 10 ml of 36 percent hydrochloric acid and, dropwise, 10 ml of 10 percent NaNo -solution. The suspension was centrifuged and washed, and the precipitate resuspended in 43 ml of 0.05 M sodium borate of pH 8.6. 'yglobulin solution prepared 7 ml were added to this suspension. The mixture was stirred for 26 hours at 4C, centrifuged, and finally washed with 1 ltr of 0.02 M phosphate buffer of pH W V p 7 d. 'otr'ni'ifififiafimofi serum. A dilution series of HCG (8-4-2-l-0.5-0.25-0 l.U./ml) was prepared with a dilution liquid consisting of one part of mans serum and 2 part of 0.05 M phosphate buffer of pH 6.2. Of each of the thus prepared HCG dilutions 0.5 ml was rotated for 2 hours at room temperature with 0.5 ml of the immuno-adsorbent suspension (4 mg/ml), prepared in accordance with c), and then centrifuged. The precipitate was washed twice, each time with 2 ml of 0.05 M phosphate buffer of pH 6.2. The precipitate was mixed with 1.0 ml of HCG-HRP solution in a suitable dilution, as well as in 0.05 M phosphate buffer of pH 6.2, and rotated again at room temperature for 2 hours.

After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 ml of it to 1.5 ml of a substrate solution consisting of 10 ul of 30% H 0 and 20 mg of 5-amino salicylic acid in ml of0.02 M phosphate buffer of pH 6.0. After 30 minutes the extinction was measured at 460 nm.

In the test system described a HCG concentration of 0.25 I.U./ml caused a measurable increase in the enzyme activity in the supernatant liquid, while a concentration of 1 I.U./ml caused the maximum increase. in this test the centrifugation step proved to be of decisive significance, as omission of this step gave rise to wrong measuring results of the enzyme activity, La. owing to turbidity of the serum and the peroxidase-like activity of it.

The HCG content of serum of pregnant women could be determined in this experimental set-up provided that the serum sample was diluted in the ratio of at least 1:3.

EXAMPLE II Determination of HCG in low concentrations by means of an enzyme/antigen coupling product.

a. Preparation of antisubstances against rabbit-yglobulin. Rabbit-y-globulin was isolated from normal rabbit serum by precipitating it with 18 percent (w/v) solid Na SO Antibodies against it were generated in a sheep. The injection scheme was:

Day Quantity Freunds adjuvant Manner of injection 0.5 mg lntramuscularly 14 0.5 mg Do.

28 1 mg Do.

42 1 mg Intravenously 56 1 mg Do.

On day 70 the sheep was exsanguinated.

b. Preparation of [sheep-anti-(rabbit-'y-globulin)]- cellulose. The 'y-globulin fraction of the sheep serum described under a) was prepared by precipitating it with 16 percent (w/v) solid sodium sulphate. This y-globulin fraction was bound to maminobenzyloxymethyl-cellulose, as described in example I c).

c. Determination of human chorionic gonadotrophin (HCG). A dilution series of HCG was prepared in 0.01 M phosphate buffer of pH 6.0, which also contained 2 percent (v/v) normal sheep serum. The dilution series was in the range of 10 to 320 I.U./ l, the dilution factor being 2. v

To 5 ml of a HCG solution was added 0.1 ml of a rabbit (anti-HCG) serum (see example I b), diluted with the same buffer to the desired strength. The mixture was left to stand at room temperature for 30 minutes, after which 1.5 mg of [sheep-anti(rabbit-y-globulin)] cellulose were added and the mixture was rotated for 2 hours.

The cellulose was centrifuged for minutes at 3,000 rpm. and resuspended in 1 ml of a solution of HCG- l-IRP coupling product, prepared in accordance with example I a), diluted to the desired strength with 0.01 M phosphate buffer of pH 6.0 with 2 percent normal sheep serum. The mixture was stirred again for 2 hours. After centrifugation the enzyme activity was determined in the supernatant liquid by adding 0.5 m] of it to 1.5 ml of enzyme substrate consisting of 10 pl of 30 percent H 0 and 20 mg of 5-amino-salicylic acid in 150 ml of 0.01 M phosphate buffer of pH 6.0. The mixture was left to stand for 30 minutes at 25, after which the extinction was measured at 460 nm. In the supernatant liquid 100 percent enzyme activity is measured provided that no anti-HCG serum is added to the system.

A dilution series of HCG, prepared with childrens urine as dilution liquid, gave an identical pattern so that also measurings in urine samples can be performed.

The centrifugation step effects a ten times higher sensitivity than can be reached in a system without centrifugation.

EXAMPLE III Determination of HCG and LH in low concentrations by means of an enzyme/antibody coupling product.

a. Preparation of the immune-adsorbent HCG cellulose. This immuno-adsorbent was prepared by the method mentioned in example I c), but instead of rabbit-y-globulin, 100 mg of HCG were coupled to 500 mg of m-aminobenzyloxymethyl cellulose.

b. Purification of antibodies against HCG. Ten ml of rabbit-anti-HCG serum, prepared in accordance with example I b), was diluted with 90 ml of 0.05 M citrate of pH 5.0 and slowly led over the immuno-adsorbent, which has packed in a column and mixed with 10 parts of Sephadex G-25. The immunoadsorbent was washed with the same buffer till no more protein was eluted. The antisubstances were eluted with 0.05 M citrate of pH 2.0. The fractions were collected in one half volume of 0.25 M NaHCO;,, tested for their content of antibodies and protein, and the suitable fractions were frozen.

c. Preparation of the coupling product (anti-HCG)- HRP. Twenty mg of horse radish peroxidase (HRP) were dissolved in 2 ml of an antibody solution having a protein content of 2 mg/ml. To this solution were added 8 pl of 25 percent glutaric aldehyde solution, after which the mixture was shaken for 2 hours at room temperature. Finally the mixture was fractionated over a Sephadex G-200 column in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme activity were bound to HCG cellulose, were used in the test system.

d. Determination of HCG and LH. Ten ml of a HCG dilution series of HCG and 10 ml ofa HCG dilution series of LH were mixed with 5 mg of anti-HCG cellulose, prepared in accordance with example I c), which was suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, and the mixtures rotate at room temperature for 2 hours. The immunoadsorbent was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0.

To the immuno-adsorbent 1 ml of the (anti-HCG)- HRP coupling product was added in the desired dilution, after which the mixture was rotated again for 2 hours. Finally, after centrifugation, the enzyme activity of the supernatant liquid was determined as described in the previous examples.

By this method a concentration of from 5 to 10 I.U. of HCG and 10 to 20 I.U. of LH per litre respectively could be determined. If the centrifugation step is omitted the optimum sample size is 0.5 nl and the sensitivity about I.U. of HCG per litre, or about 200 I.U. of LH per litre, so that the method according to the invention yields a 10-20 fold increase in sensitivity.

EXAMPLE IV Determination of HCG and anti-HCG.

a. Rabbit-serum was fractionated over DEAE cellulose in accordance with the prescription of H.A. Sober and others in J. Am. Chem. Soc. 78, 756 (1956). The isolated y-globulin fraction, which was immuno-electrophoretically pure, was partly used for generating antibodies in a sheep in accordance with the scheme of example [I a), while besides 100 mg of rabbit-y-globulin was coupled to 500 mg of m-aminobenzyloxymethyl cellulose by the method described in example I c).

From the sheep [anti-(rabbit-y-y-globulin)] serum prepared the specific antibodies were isolated by the method described in example II b) with the immune-adsorbent III b. The coupling product [anti-(rabbit-y-globulinH- HRP was prepared analogous to the coupling product (anti-HCG)-HRP, described in example lll c).

0. Determination of anti-HCG. A dilution series of rabbit-(anti-HCG) serum was prepared with 0.05 M phosphate buffer of pH 6.0.

Rabbit-(anti-HCG) serum (0.5 ml) was rotated with 0.25 mg of HCG-cellulose for 2 hours (see example 111 a). The reaction mixture was centrifuged and the precipitate washed four times with phosphate buffer, each time with 3 ml, after which the precipitate was resuspended in 1 ml of a solution of the coupling product b. The mixture obtained was again rotated for 2 hours. After centrifugation the enzyme activity in the supernatant liquid was determined, as described in example l d).

d. Determination of HCG. With the reagents prepared, HCG was determined by incubating solutions of it with 0.5 ml of rabbit-(anti-HCG)-serum in a dilution which in the system described under just causes an almost maximum reduction in enzyme activity in the supernatant liquid, and performing the process described under c) with the mixture obtained.

Where use was made of ml of HCG solution, it

proved to be possible to demonstrate concentrations of about 1.U./l of HCG.

EXAMPLE v Determination of insulin in serum.

a. Preparation of insulin-(glucose-oxidase). Five mg of hog insulin and 25 ml of glucose-oxidase were dissolved in 2 ml of 0.05 M phosphate buffer of pH 6.5. To this solution 5 'yl of 25 percent glutaraldehyde solution were added, after which the mixture was shaken at room temperature for 90 minutes. The mixture was fractionated over Sephadex G-200 in 0.05 M phosphate buffer of pH 6.5. The fractions whose highest percentage of enzyme ac tivity could be bound by antibodies against insulin were used in the test system.

b. Preparation of antibodies against insulin. Ten caviae were injected intramuscularly, once a week, with 1 mg of hog insulin in complete Freunds adjuvant, over a period of from 4 to 8 weeks. After having been left alone for 2 weeks the animals were injected intravenously with another milligram of insulin without adjuvant. Another 2 weeks later the animals were exsanguinated. Hypoglycemia occurring occasionally was combated by intraperitoneal administration of glucose.

c. Preparation of anti-substances against cavia 'y-globulin. Cavia -y-globulin was prepared by adding one volume of a saturated ammonium sulphate solution to two volumes of cavia serum. The resulting precipitate was washed twice with 33 percent saturated (NH S0 solution and then taken up in a physiological salt solution. A sheep was immunized with increasing dosages of the 'y-globulin prepared, viz. 0, 5, 1 and 2 mg. The injections were given every 2 weeks, the immunogen being mixed with complete Freunds adjuvant. Two weeks after the last injection another 2 mg of y-globulin, in a physiological salt solution, were given. One week later the animal was exsanguinated.

d. Preparation of insoluble antibodies against cavia 'y-globulin. Ten gm of microcrystalline cellulose were activated by adding it, while stirring, to 400 ml of 2.5 percent (w/v) CNBr solution, after which the pH was adjusted to 10.5 with an 1 N NaOH- solution, and it was maintained at it for 2 minutes. The cellulose was washed with ice water and with 0.1 M NaHCO;,. To 10 ml of sheep-anti-(cavia y-globulin) serum 1.6 gm of NaSO, were added. After stirring for 1 hour at room temperature the precipitate was centrifuged, washed twice with 20 ml of 16 percent (w/v) Na SO. solution, and finally taken up in 10 ml of 0.1 M NaHCO;,.

The activated cellulose was mixed with 40 ml ofa 0.1

M NaHCO;, solution and the 10 ml of y-globulin solution. This suspension was rotated for 40 hours at 4C and washed, twice with 5 ml of 0.5 M NaHCO twice with 500 ml of 0.05 M citrate of pH 1.1, and two times with 500 ml of 0.05 M phosphate of pH 6.2.

e. Determination of insulin in serum. Four ml of an insulin dilution series in the range of from O-lOO ng/ml, were incubated at room temperature, for 4 hours, with 1.0 ml ofanti-insulin serum (with 0.15 M phosphate buffer of pH 6.0, diluted to the desired strength). After that 5 mg of the immunoadsorbent prepared under a), suspended in 1 ml of 0.15 M phosphate buffer of pH 6.0, were added, and the resulting mixture rotated overnight at 4C. Then the immuno-adsorbent was centrifuged and washed three times with 5 ml of 0.05 M phosphate buffer of pH 6.0 (each time with 5 ml), to which 2 percent sheep serum had been added. After that 1.0 ml of insulin-glucose oxidase, diluted to the desired strength with the wash buffer, was added to the immunoadsorbent. The mixture obtained was again rotated overnight and centrifuged, after which the enzyme activity in the supernatant liquid was measured by incubating 0.5 ml of it with 2.5 ml of a substrate solution, and the extinction measured at 460 nm. The substrate solution contained mg of glucose, 10 ugm of peroxidase and 1 mg of S-aminosalicylic acid per 2.5 ml of 0.05 M phosphate buffer of pH 6.0.

The centrifugation step, in this case serving both to raise the maximum volume of the test liquid to be employed and to remove serum factors disturbing the reaction, caused a lO-fold increase in sensitivity, so that a concentration of a few ng/ml of insulin could be demonstrated.

EXAMPLE VI Determination of oestradiol.

a. Preparation of oestradiol-l7-succinyl-l-1RP. Fifty mg of oestradiol-l7-haemisuccinate and 0.08 ml of tri-n-butylamine were dissolved in 2.5 ml of diox ane. To the cold solution (2C) 15 u] of isobutylchlorocarbonate were added. After 30 minutes this solution was mixed with mg of horse radish peroxidase (HRP) in 7.5 ml of a mixture of dioxane and water (2:3), which had been adjusted to pH 9.5 with caustic soda. This solution was stirred for 4 hours at 2C, after which it was dialysed for 18 hours. The precipitate obtained after the pH of the dialysate had been adjusted to 4.6 was centrifuged, washed, and taken up in 5 ml of distilled water, which had been adjusted to pH 8. The material was purified further by precipitating it twice with 10 ml of acetone. The ultimate product was taken up in 10 ml of 0.05 M phosphate buffer of pH 7.8.

b. Preparation of oestradiol-l7-succinyl-BSA. The preparation was prepared by the mixed anhydride method as described under a). The starting material was 100 mg of oestradiol-l7-haemisuccinate and mg of bovine serum albumin (BSA).

0. Preparation of anti-substances against oestradiol. A sheep was injected every 4 weeks with 4 mg of oestradiol-l7-succinyl-BSA in complete Freunds adjavant. With regular intervals blood was taken from the sheep. The serum was adsorbed with BSA.

Day Quantity Freund's adjuvant Manner of injection 200 ugm lntramuscularly 14 400 ugm Do.

28 800 tgm Do.

42 800 agm lntravenously Two weeks after the last injection the animals were exsanguinated.

e. Preparation of the immuno-adsorbent [rabbitanti(-sheep-y-globulin)] cellulose.

The 'y-globulin fraction of the anti-sera described under 12) was prepared by precipitation with 18 percent w/v Na SO The product obtained was coupled with cellulose by Gurvichs method described in example I c).

f. Determination of oestradiol. A dilution series of oestradiol (00.5124-8l6 ng/ml) was prepared in phisphate buffer of pH 6.0. Five ml of sample were mixed with 0.5 ml of the sheep-antioestradiol-serum in the desired dilution. After incubating the mixture for 2 hours at room temperature 1 ml of immunoadsorbent suspension (see e) of 60 mg/ml was added, after which the mixture was rotated for 4 hours at room temperature. The cellulose was centrifuged and washed with 5 ml of 0.05 M phosphate buffer of pH 6.0 containing 2 percent BSA. Then 1 ml of oestradiol-17-succinyl- HRP, diluted to the desired strength with the buffer with which the mixture was washed, was added to the cellulose. The mixture was rotated for 1 hour, after which it was centrifuged again and the enzyme activity in the supernatant liquid was measured as described in example I.

By the method described concentrations of 1 ng/ml of oestradiol could be demonstrated, which means an increase in sensitivity by a factor 10, compared with the test without centrifugation step.

EXAMPLE Vll Determination of cortisol.

a. Preparation of cortisol-21-galactose-oxidase.

Fifty mg of cortisol-2l-haemisuccinate and 100 mg of galactose-oxidase were coupled by the mixed anhydride method as described in example VI a).

b. Preparation of insoluble transcortine. One hundred mg of transcortine purified by DEAE cellulose chromatography, followed by hydroxylapatite chromatography, were coupled with 3 gm of Sepharose 4B by the CNBr method: Sepharose 4B suspension (3 gm) was activated by mixing it with 4 ml of 2.5 percent (w/v) CNBr-solution in distilled water, after which the pH was adjusted to 1 N NaOH between 10 and 11, at which value it was maintained for 6 minutes. Then the Sepharose was washed with ice-water and with 0.1 M NaHCO;,, after which mg of transcortine in 20 ml 0g 0.1 M NaHCO:, were added, and the suspension was shaken at 4C for 24 hours, After being washed successively with 0.5 M NaHCO;,, 0.05 M citrate buffer of pH 1.1 and 0.05 M phosphate buffer of pH 6.0, the Sepharose was kept in the last buffer, to which 0.1 percent merthiolate had been added.

0. Determination of cortisol. A cortisol dilution series, in the range of from 0.25-16 ng/ml was prepared in 0.05 M phosphate buffer of pH 6.0. File ml of each cortisol solution (in 0.5 M phosphate buffer of pH 6.0) were rotated overnight with 5 mg of transcortine-Sepharose, at 4C. After centrifugation 1 ml of cortisol-2l-galactose oxidase solution, diluted to a suitable concentration in the buffer mentioned before, was added, after which the mixture was rotated for 2 hours at 4C. After recentrifugation the enzyme activity in the supernatant liquid was determined by adding 0.5 ml of it to 1.5 ml of substrate constisting of 100 mg of D- galactose, 20 mg of S-amino-salicylic acid and 10 ugm of peroxidase in ml of 0.02 M phosphate buffer of pH 6.0. Finally, after 30 minutes, the extinction was measured at 460 nm.

By this method about 1 ng/ml cortisol could be demonstrated, which means an increase in sensitivity by a factor 10.

We claim:

1. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:

a. providing a given quantity of the binding partner of the component to be determined, which binding partner is in an insoluble form;

b. reacting the component to be determined with its binding partner to form a reaction mixture having a solid phase and a liquid phase;

c. separating the solid phase from the liquid phase;

d. adding to said solid phase a given quantity of a coupling product of the component to be determined with an enzyme; and

e. determining the enzyme activity of the solid phase which is a measure of the quantity of reaction component to be determined.

2. Process for the demonstration and determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance, and a protein capable of binding said bindable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein, comprising the steps of:

a. providing a given quantity of the binding partner of the component to be determined in a soluble form;

b. adding a given quantity of an antibody against said binding partner, which antibody is in an insoluble 14 sure of the quantity of the reaction component to be determined.

3. The process of claim 1 in which the enzyme is an oxido-reductase.

4. The process of claim 2 in which the enzyme is an oxido-reductase.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3654090 *24 Sep 196820 Jul 1982 Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3875011 *1 Feb 19741 Apr 1975Syva CoEnzyme immunoassays with glucose-6-phosphate dehydrogenase
US3904367 *15 Aug 19739 Sep 1975Gen ElectricContrast enhancement for immunological film detection
US3951748 *11 Nov 197420 Apr 1976Medical Products, Inc.Sensitized matrix for detection of disease
US4016043 *4 Sep 19755 Apr 1977Akzona IncorporatedEnzymatic immunological method for the determination of antigens and antibodies
US4039652 *11 Oct 19732 Aug 1977Miles Laboratories, Inc.Antigens, antibodies
US4116776 *19 Apr 197626 Sep 1978International Radioimmune Systems, Inc.Cancer detection
US4200508 *9 Feb 197829 Apr 1980Hidematsu HiraiImmunodiffision
US4203802 *5 Dec 197720 May 1980Syva CompanyEnzyme bound to an estrogen ligand
US4240751 *9 Nov 197823 Dec 1980Akzona IncorporatedMethod and apparatus for specific binding substances
US4248965 *3 Oct 19773 Feb 1981Mochida Seiyaku Kabushiki KaishaImmunochemical process of measuring physiologically active substances
US4254223 *16 Apr 19793 Mar 1981Akzona IncorporatedV-shaped transparent vessel
US4269938 *8 Mar 197926 May 1981Eastman Kodak CompanyAssay of peroxidatively active materials
US4275149 *24 Nov 197823 Jun 1981Syva CompanyImmunoassay
US4289748 *31 May 197915 Sep 1981United States Of AmericaUltrasensitive enzymatic radioimmunoassay method
US4302534 *7 Mar 197824 Nov 1981Israel Institute For Biological ResearchRedox system comprising a phenolic compound, peroxidase, and an antibody or antigen
US4318707 *3 Jun 19809 Mar 1982Syva CompanyImmunoassay employing absorption particles
US4323647 *15 Oct 19806 Apr 1982University Of MiamiSteric hindrance enzyme immunoassay
US4331444 *3 Mar 198025 May 1982Fuji Photo Film Co., Ltd.Competitive immunoassay using silver halide fogging agent
US4337063 *3 Mar 198029 Jun 1982Fuji Photo Film Co., Ltd.Competitive immunoassay using spectral sensitizer label
US4343896 *1 May 198010 Aug 1982Akzona IncorporatedMethod and test pack for the demonstration and determination of an antigen or antibody
US4362531 *14 Apr 19817 Dec 1982Technicon Instruments CorporationAgglutination immunoassays carried out with agent to reduce non-specific interferences
US4374925 *9 Feb 198122 Feb 1983Syva CompanyMacromolecular environment control in specific receptor assays
US4376110 *4 Aug 19808 Mar 1983Hybritech, IncorporatedForming a ternary comples between solid phase antibody, antigen, and lebelled antibody
US4446232 *13 Oct 19811 May 1984Liotta Lance AEnzyme immunoassay with two-zoned device having bound antigens
US4446238 *25 Jan 19821 May 1984Janssen Pharmaceutica N.V.Bright field light microscopic method of localizing tissue antigens
US4452886 *21 Sep 19815 Jun 1984Henry Robert PLigands and receptors in chromophoric or fluorescent group-containing polymers
US4469787 *14 May 19824 Sep 1984Mallinckrodt Inc.Direct, two-site; medical diagnosis
US4474878 *29 Sep 19752 Oct 1984Cordis Laboratories, Inc.Sandwich EIA for antigen associated with hepatitis
US4486530 *24 Jun 19814 Dec 1984Hybritech IncorporatedImmunometric assays using monoclonal antibodies
US4503143 *20 Aug 19825 Mar 1985Btc Diagnostics Limited PartnershipEnzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4506009 *30 Mar 198219 Mar 1985University Of CaliforniaDetermination of antibiotics, steroids, vitamins, viruses
US4517288 *23 Jan 198114 May 1985American Hospital Supply Corp.Chromatography
US4530900 *13 Sep 198223 Jul 1985Seragen Diagnostics Inc.Determining soluble antigen in sample; complexing; precipitating
US4592995 *16 Nov 19833 Jun 1986Dainippon Pharmaceutical Co., Ltd.Reagent for streptococcal anti-esterase assay
US4604365 *28 May 19825 Aug 1986Electro-Nucleonics, Inc.Immunoprecipitation assay
US4642285 *2 May 198410 Feb 1987Diamedix CorporationEnzyme-immunoassay
US4665020 *30 May 198412 May 1987United States Department Of EnergyFlow cytometer measurement of binding assays
US4713347 *14 Jan 198515 Dec 1987Sensor Diagnostics, Inc.Measurement of ligand/anti-ligand interactions using bulk conductance
US4753875 *26 Jul 198528 Jun 1988Ryan James WMethod for assaying proteases with tagged proteinaceous inhibitors
US4808522 *23 Apr 198628 Feb 1989Moskovsky Gosudarstvennx Universitet Imeni M. V. Lomonoso VACrosslinking antibody
US4812395 *19 Aug 198614 Mar 1989E. I. Du Pont De Nemours And CompanyRefractive particles with ligand coating
US4812396 *2 Jul 198714 Mar 1989E. I. Du Pont De Nemours And CompanyRefractive particles with ligand coating
US4824784 *9 Nov 198725 Apr 1989Hygeia Sciences, IncorporatedChromogenic solution for immunoassay
US4868108 *12 Dec 198519 Sep 1989Hygeia Sciences, IncorporatedMultiple-antibody detection of antigen
US4931385 *21 Nov 19885 Jun 1990Hygeia Sciences, IncorporatedEnzyme immunoassays and immunologic reagents
US5047330 *6 Jan 198810 Sep 1991Commissariat A L'energie AtomiqueCompound labelled by the acetyl cholinesterase of Electrophorus electricus, its preparation process and its use as a tracer or marker in enzymoimmunological determinations
US5102788 *28 Apr 19897 Apr 1992Hygeia Sciences, Inc.Of immunoreactive component, an organic performance enhancer and a sugar to prevent agglomeration; homogeneity, shelf life
US5328828 *20 Jul 199212 Jul 1994Syntex (U.S.A.) Inc.Immunoassay for amphetamines with antibodies for conjugation and enzymes
US5334513 *3 Sep 19922 Aug 1994Syntex (U.S.A.) Inc.Measuring migration distance between zones
US5348867 *15 Nov 199120 Sep 1994George GeorgiouExpression of proteins on bacterial surface
US5451507 *10 May 199419 Sep 1995Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5468647 *1 Sep 199421 Nov 1995Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5534405 *18 Nov 19949 Jul 1996The Scripps Research InstituteAntibodies, diagnostic systems and methods for assaying HBxAg
US5610077 *19 Jul 199411 Mar 1997Unilever Patent Holdings B.V.Immunoassay
US5614504 *21 Apr 199525 Mar 1997The University Of South FloridaMethod of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5624809 *5 May 199529 Apr 1997Behringwerke AgDevice for immunochromatographic analysis
US5672475 *20 Jan 199530 Sep 1997Chiron Diagnostics CorporationMixed luminescent conjugate test
US5698686 *28 Apr 199516 Dec 1997Arch Development CorporationYeast telomerase compositions
US5726015 *10 Jan 199510 Mar 1998Vanderbilt UniversityMethod to determine metastatic potential of tumor cells
US5726023 *6 Jun 199510 Mar 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5728807 *21 Jun 199517 Mar 1998Ramot-University Authority For Applied Research And Industrial Development, Ltd.Genetic disorders
US5777093 *28 Jul 19957 Jul 1998Ramot-University Authority For Applied Research & Industrial Development Ltd.cDNAs associated with ataxia-telangiectasia
US5801005 *31 Mar 19951 Sep 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5807552 *4 Aug 199515 Sep 1998Board Of Regents, The University Of Texas SystemCompositions for conferring immunogenicity to a substance and uses thereof
US5837535 *15 Feb 199617 Nov 1998Henry Ford Health SystemNeuronal-neonatal gene: neuronatin
US5840322 *19 Dec 199624 Nov 1998Ramot-University Authority For Applied Research & Industrial Devel. Ltd.Anti-oral-microbial adhesion fraction derived from vaccinium
US5843673 *7 Jun 19951 Dec 1998Curators Of The University Of MissouriMethod of screening for endometriosis
US5846538 *7 Jun 19958 Dec 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US5858661 *8 Apr 199612 Jan 1999Ramot-University Authority For Applied Research And Industrial DevelopmentIsolation, purification, cloned nucleic acid sequence with mutation causing protein truncation or no initiation; detecting carriers by analysis of nucleic acids isolated from patients with hereditary muscular disorders
US5869445 *1 Apr 19969 Feb 1999University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5874423 *12 Sep 199623 Feb 1999Yissum Research Development Co. Of The Hebrew University Of JerusalemCardiotonic agent
US5876712 *6 Jun 19952 Mar 1999University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5916752 *26 Sep 199729 Jun 1999Arch Development CorporationTelomerase screening methods
US6075122 *6 Jun 199513 Jun 2000University Of WashingtonA peptide for the detection, monitoring, and treatment of cancer in animals; anticarciongenic agents
US61875634 Aug 199913 Feb 2001Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US62007493 May 199613 Mar 2001Ramot-University Authority For Applied Research And Industrial Development Ltd.Ajusted nucleic acid sequence; for detection of genome adjustments and preferential genetic disorders
US62844962 Jan 19984 Sep 2001University Of South FloridaPlasmid for detecting adjustments in open reading frame; for use in evaluation of polymerase chain reaction products
US631290110 Sep 19996 Nov 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US63312753 Aug 200018 Dec 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US634234921 Jul 199829 Jan 2002Burstein Technologies, Inc.A solid support substrate containing a cleavable signal element, a signal responsive moiety and a cleavable spacer; analytes bind the signal element, anchoring the responsive moiety to the element substrate-attaching end after cleavage
US63444438 Jul 19995 Feb 2002University Of South FloridaPeptide antagonists of tumor necrosis factor alpha
US638761930 Jun 199914 May 2002Arch DevelopmentTelomerase compositions and methods
US63915638 Dec 199321 May 2002Akzo Nobel N.V.Method for the determination of antigens with the aid of three or more monoclonal antibodies
US64069207 Aug 199618 Jun 2002Inverness Medical Switzerland GmbhProcesses and apparatus for carrying out specific binding assays
US6440682 *24 May 200027 Aug 2002Detroit R&D Inc.Detection of hypertension using immunoreactive metabolic products
US648238916 Oct 199819 Nov 2002University Of South FloridaMethod to diagnose and monitor cellular immune deficiencies
US653127719 Mar 199811 Mar 2003The Curators Of The University Of MissouriEndometriosis-specific secretory protein
US661083815 Sep 199826 Aug 2003Symbicom AktiebolagIsolated nucleic acid encoding polypeptides which bind with a rabbit polyclonal antibody raised against another polypeptide; use in vaccines as well as diagnostic compositions and kits
US665647116 Nov 19992 Dec 2003Board Of Regents, The University Of Texas SystemMonitoring HLA-Cw7-restricted CTL response; AIDS prevention
US666437015 Jul 199916 Dec 2003University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US668975728 Dec 199810 Feb 2004M.L. Laboratories PlcMethods for vaccination and vaccines therefor
US674073823 Dec 200225 May 2004Quark Biotech, Inc.Antibodies binding to polypeptides encoded by the genes
US67706228 Jun 20013 Aug 2004Gary A. JarvisTumors, and metastasis
US67873181 Jun 20007 Sep 2004Roskamp Research Institute, LlcAssay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US686700524 Oct 200115 Mar 2005Beckman Coulter, Inc.In which the presence, absence, activity or concentration of a target analyte is assayed by the emission or quenching of a light signal, or by a change of a light signal in two or more time intervals; automated biological binding tests
US687558218 Aug 20005 Apr 2005Omniscience Pharmaceuticals, Inc.Identifying drug resistant microorganisms and mechanisms of evolution; improving antitumor and bactericidal agents
US69535736 Oct 199811 Oct 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US699217613 Feb 200231 Jan 2006Technion Research & Development Foundation Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US69982324 Apr 200114 Feb 2006Quark Biotech, Inc.determining, in a sample from a human subject, the level of expression of at least two polynucleotides, wherein a higher level of expression of the polynucleotides compared to cancer free human polynucleotide expression is an indication of cancer
US703374711 Apr 200225 Apr 2006Nagaoka & Co., LtdApparatus for use in the detection of preferential targets in sample
US70604621 Nov 200113 Jun 2006National University Of SingaporeAgrobacterium tumefaciens outer membrane protein;
US708739516 Jan 20018 Aug 2006Quest Diagnostics Investments IncorporatedDetermination concentration of vitamin d; releasing using aqueous base; solvent-free; coupling to antibody; detection signal
US710183929 Aug 20005 Sep 2006Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US71381449 Sep 200221 Nov 2006Nadir AskenasyRestricting outflow of fluid from a portion of the circulatory system; administering a dose of bone marrow cells derived from donor to a body part delimiting portion of circulatory system, prior to, concomitantly with or following transplantation
US722390215 Nov 200029 May 2007Yissum Research Development Company Of The Hebrew University Of JerusalemGene expression of nucleic acid construct into a host cell comprising polynucleotide encoding polypeptide having a beta -glucosidase catalytic activity; genetic engineering; alcoholic beverages
US724770321 Aug 200324 Jul 2007University Of WashingtonAnticancer agents; protein complex
US727081028 Dec 200018 Sep 2007Yeda Research And Development Co. Ltd.Veto cells effective in preventing graft rejection and devoid of graft versus host potential
US72947012 Apr 200313 Nov 2007Technion Research & Development Foundation Ltd.Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
US730680429 Sep 200311 Dec 2007Board Of Regents, The University Of Texas SystemHIV-specific T-cell induction
US734797222 Jul 199825 Mar 2008Jin Po LeeMultiple analyte assay device
US73550795 Apr 20058 Apr 2008The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US738510610 Jan 200110 Jun 2008Ramot At Tel Aviv University Ltd.Comprises nucleotide sequences coding polypeptied for use in generation of stress and drought resistant plant
US742313920 Jan 20049 Sep 2008Insight Biopharmaceuticals Ltd.Expresion vector comprising nucleotide sequences coding secreted glycoprotein hormone with modified untranslated region for use in enhancement of blood production; directed protein evolution
US744278115 Aug 200228 Oct 2008Urifer Ltd.Diagnosis, prevention and treatment of cancer
US749842820 Jun 20043 Mar 2009Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US753460517 May 200519 May 2009Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US753460911 Apr 200519 May 2009Pluristem Life Systems Inc.Method of expanding undifferentiated hemopoietic stem cells
US75539401 Feb 200730 Jun 2009Modigene Inccomprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO (erythropoietin) peptide ; improving a biological half life of an hGH polypeptide
US75539411 Feb 200730 Jun 2009Modigene IncLong-acting polypeptides and methods of producing same
US755400722 Nov 200530 Jun 2009Evogene Ltd.by expressing within the plant an exogenous polynucleotide homologous to SEQ ID NO:13;
US76016973 May 200513 Oct 2009University Of WashingtonPolypeptides; nucleic acid molecules and viral vectors which direct gene expression of such polypeptides; vaccines; genetic engineering; transfecting cells of animal ex vivo with nucleic acid molecule and delivering transfected cells animal
US760514913 Jul 199920 Oct 2009University Of South FloridaModulation of the phospholipase A2 pathway as a therapeutic
US761172320 Mar 20033 Nov 2009Nanocyte Inc.Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US762570727 Sep 20041 Dec 2009Ramot At Tel Aviv University Ltd.Identifying site of interaction between bacterial toxin and antitoxin polypeptides thus enabling ability to identify or design novel antibiotics which target this site of interaction and thus enable bacterial cell killing; identifying agents with activity against antibacterial drug-resistant strains
US763252210 Jan 200615 Dec 2009Nanocyte Inc.Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US76329239 Mar 200515 Dec 2009Technion Research & Development Foundation Ltd.Lymphotropic retrovirus disease treatment and diagnosis such as acquired immunodeficiency syndrome (AIDS); Specifically binds with high specificity and affinity a particular human APM:pathogen-derived antigen complex
US763812425 Mar 200429 Dec 2009Technion Research & Development Foundation Ltd.Specifically binds with high specificity and affinity a particular human APM:pathogen-derived antigen complex
US765522519 Feb 20082 Feb 2010Gamida Cell, Ltd.Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US765523921 Jun 20072 Feb 2010University Of WashingtonPeptides for use in diagnosis, prevention and treatment of cell proliferative disorders
US767857311 Apr 200516 Mar 2010Pluristem Ltd.Using plug flow bioreactor system which mimics bone marrow microenvironment for propagation and maintenance of stromal cells
US768705717 Dec 200230 Mar 2010Yissum Research Development Company Of The Hebrew University Of JerusalemIn vitro micro-organs, and uses related thereto
US769592717 Mar 200613 Apr 2010Detroit R & DDetection of hypertension using glucuronidated metabolic products
US771877718 Oct 200618 May 2010Technion Research & Development Foundation Ltd.MHC-peptide complex binding ligands
US778139621 Jun 200624 Aug 2010Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated disease
US778140211 Oct 200524 Aug 2010Closed Loop Therapies Ltd.Methods and implantable devices for treating supraventricular arrhythmias
US778626731 Jan 200831 Aug 2010Baylor Research InstituteMultivariable antigens complexed with targeting humanized monoclonal antibody
US779067312 Jun 20067 Sep 2010New York UniversityMethods and compositions relating to cystatin C
US781198129 Sep 200412 Oct 2010Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US785507519 May 200821 Dec 2010Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US78880032 Sep 200515 Feb 2011The United States Of America As Represented By The Department Of Health And Human ServicesMethods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
US789324025 Jul 200822 Feb 2011Insight Biopharmaceuticals Ltd.High level expression of recombinant human erythropoietin having a modified 5′-UTR
US791080015 Aug 200622 Mar 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US792808316 Jan 200819 Apr 2011Yissum Research Development Company Of The Hebrew University Of JerusalemH19 silencing nucleic acid agents for treating rheumatoid arthritis
US794749930 Nov 200324 May 2011Technion Research & Development Foundation Ltd.Method of dynamically culturing embryonic stem cells
US79558529 Feb 20047 Jun 2011Gamida Cell Ltd.Expansion of stem cells; prevent cell differentiation; culturing
US800090030 Dec 200516 Aug 2011Microsoft CorporationAssociation-based predictions of pathogen characteristics
US80078477 Aug 200630 Aug 2011Eytan BidermanFeeding formula appliance
US80129292 Jul 20096 Sep 2011Tel Aviv University Future Technology Development L.P.Peptides directed for diagnosis and treatment of amyloid-associated diseases
US80175865 Jan 200913 Sep 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US801981816 Jan 200713 Sep 2011Zlango Ltd.Communications network system and methods for using same
US803491421 Sep 200611 Oct 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US803924028 Sep 200518 Oct 2011Yissum Reseach Development Company Of The Hebrew University Of JerusalemRNA degrading polypeptides for use in prevention and treatment of arthritis, inflammation, restenosis, nervous system and cell proliferative diseases
US80535542 Jan 20098 Nov 2011Ramot At Tel-Aviv University Ltd.Peptide nanostructures and methods of generating and using the same
US80577981 Feb 200815 Nov 2011Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US806266015 Mar 200622 Nov 2011Nanocyte Inc.Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US80675736 Jul 200629 Nov 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19 and methods of using same
US806757416 Jan 200829 Nov 2011Yissum Research Development Company Of The Hebrew University Of JerusalemNucleic acid agents for downregulating H19, and methods of using same
US80713236 Apr 20076 Dec 2011The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US808041729 Nov 200620 Dec 2011Gamida-Cell Ltd.Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells
US80881602 Jun 20093 Jan 2012Multi-Gene Vascular Systems Ltd. (“MGVS”)Drug-eluting intravascular prostheses and methods of use
US81295149 Feb 20096 Mar 2012Evogene Ltd.Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US815338318 Mar 200910 Apr 2012Wisconsin Alumni Research FoundationMycobacterial culture screening test for Mycobacterium avium complex bacteria
US815837114 Oct 201017 Apr 2012Wisconsin Alumni Research FoundationAssay for antibodies to Mycobacterium paratuberculosis
US816349427 Nov 200324 Apr 2012Technion Research & Development Foundation Ltd.Method for assessing metastatic properties of breast cancer
US816818030 Sep 20091 May 2012Technion Research & Development Foundation Ltd.Methods and compositions for modulating angiogenesis
US816885720 Dec 20071 May 2012Evogene Ltd.for improving fiber quality and/or yield of a fiber producing plant, as well as methods of using such polynucleotides for producing plants having increased biomass/vigor/yield
US81781285 Dec 200215 May 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Nanoparticles containing polymeric nucleic acid homologs
US81933117 Feb 20115 Jun 2012Yissum Research Development Company Of The Hebrew University Of JerusalemCD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US82027246 Oct 201019 Jun 2012Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US823654327 Sep 20107 Aug 2012Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US82369342 Feb 20087 Aug 2012Baylore Research Institutecomplexing of multiple antigens or proteins in a controlled, multivariable fashion, to one single primary recombinant monoclonal antibody; activate dendritic cells and other cells; bound to one half of a Coherin/Dockerin pair
US82525887 Apr 200428 Aug 2012Yeda Research And Development Co. Ltd.Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
US829320922 Oct 200923 Oct 2012Segev Laboratories LimitedSystem for delivering therapeutic agents into living cells and cells nuclei
US832363628 Jul 20114 Dec 2012Prolor Biotech Ltd.Long-acting interferons and derivatives thereof and methods thereof
US835203124 May 20078 Jan 2013Impulse Dynamics NvProtein activity modification
US83673928 Sep 20095 Feb 2013Transalgae Ltd.Genetic transformation of algal and cyanobacteria cells by microporation
US837532716 Jan 200612 Feb 2013Zlango Ltd.Iconic communication
US83889548 Apr 20045 Mar 2013Laboratoire Francais Du Fractionnement Et Des BiotechnologiesStabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form
US841531820 Jun 20119 Apr 2013Vascular Biogenics Ltd.Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US842616627 Jul 201123 Apr 2013Prolor Biotech Inc.Long-acting polypeptides and methods of producing same
US842668219 Apr 201223 Apr 2013Evogene Ltd.Isolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
US844988816 Sep 201128 May 2013Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US84502692 Aug 201128 May 2013Prolor Biotech Ltd.Long-acting growth hormone and methods of producing same
US84613031 Aug 200811 Jun 2013Gilead Biologics, Inc.LOX and LOXL2 inhibitors and uses thereof
US846594828 Jul 201118 Jun 2013Prolor Biotech Ltd.Long-acting veterinary polypeptides and methods of producing and administering same
US847853530 Dec 20052 Jul 2013Microsoft CorporationSystems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US848131422 Feb 20089 Jul 2013Baylor Research InstituteUsing low density lipoprotein receptor specific immunoglobulin to increase receptor expression on antigen presenting cells; immunotherapy; treating infection, autoimmune, graft vs host and allergic disorders
US84818123 Jun 20099 Jul 2013Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants generated thereby
US851299020 Aug 201020 Aug 2013Gilead Biologics, Inc.Catalytic domains from lysyl oxidase and LOXL2
US85134889 Apr 200820 Aug 2013Evogene Ltd.Polynucleotides, polypeptides and methods for increasing oil content, growth rate and biomass of plants
US85244914 Sep 20093 Sep 2013University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US85632739 Apr 200922 Oct 2013Tel Aviv University Future Technology Development L.P.Method of screening for compounds that disaggregate amyloid aggregates
US858605224 Apr 201219 Nov 2013Baylor Research InstituteVaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
US86178671 Jan 201231 Dec 2013Yissum Research Develpment Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US86423308 Aug 20064 Feb 2014Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US86581676 Dec 201225 Feb 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US86794851 Aug 200825 Mar 2014Gilead Biologics, Inc.Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US86800621 Jun 200725 Mar 2014Deliversir Ltd.System for delivering therapeutic agents into living cells and cells nuclei
US86802464 Feb 201125 Mar 2014Gilead Biologics, Inc.Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US868540227 Jul 20091 Apr 2014Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
US868622724 Jul 20081 Apr 2014Evogene Ltd.Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
US869763422 Dec 200915 Apr 2014Tel Aviv University Future Technology Development L.P.Peptides and methods using same for diagnosis and treatment of amyloid-associated disease
US872232423 Dec 201013 May 2014The United States Of America, As Represented By The Secretary Department Of Health And Human ServicesMethods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
US872848117 Jul 201220 May 2014Baylor Research InstituteAgents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
US87351279 Sep 201327 May 2014Yissum Research Development Company Of The Hebrew University Of JerusalemMethods of and compositions for inhibiting the proliferation of mammalian cells
US87478555 Apr 200910 Jun 2014Technion Research & Development Foundation LimitedAnti human immunodeficiency antibodies and uses thereof
US875929214 Feb 201224 Jun 2014Prolor Biotech, LlcLong-acting coagulation factors and methods of producing same
US877552616 Jan 20078 Jul 2014Zlango Ltd.Iconic communication
US88086995 Apr 201119 Aug 2014The University Of ChicagoCompositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US88158239 Mar 201226 Aug 2014Technion Research & Development Foundation Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
US883486219 Apr 200516 Sep 2014Nanocyte Inc.Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
USRE31006 *2 Mar 19783 Aug 1982Akzona IncorporatedProcess for the demonstration and determination of reaction components having specific binding affinity for each other
USRE32696 *22 Dec 197814 Jun 1988Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
DE2643829A1 *29 Sep 197614 Apr 1977Cordis CorpVerfahren zum feststellen der anwesenheit eines der hepatitis zuzuordnenden antigens
EP0060700A1 *12 Mar 198222 Sep 1982Immuno-Mycologics, Inc.Assay method and device
EP1683874A229 Aug 200126 Jul 2006YEDA RESEARCH AND DEVELOPMENT Co. LTD.Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
EP2050826A213 Oct 200822 Apr 2009Roche Diagnostics GmbHReagents and methods for detecting neisseria gonorrhoeae
EP2058275A17 Jan 200413 May 2009Ramot at Tel-Aviv University Ltd.Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP2062918A227 Nov 200327 May 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2062919A227 Nov 200327 May 2009Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
EP2071021A212 Dec 200817 Jun 2009University of South FloridaBone marrow-derived neuronal cells
EP2072045A211 Feb 200324 Jun 2009Technion Research and Development Foundation, Ltd.Antibody having a t-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP2149585A14 Nov 20043 Feb 2010Novartis Vaccines and Diagnostics, Inc.Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP2174668A214 Nov 200514 Apr 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
EP2182052A17 Oct 20035 May 2010Technion Research and Development Foundation, Ltd.Human foreskin cells suitable for culturing stem cells
EP2186530A115 Nov 200119 May 2010Vascular Biogenics Ltd.Promoters exhibiting endothelial cell specificity and methods of using same
EP2208782A24 Feb 200021 Jul 2010Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2216033A24 Mar 200411 Aug 2010Yeda Research and Development Co. Ltd.Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
EP2243491A14 Nov 200427 Oct 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
EP2243492A14 Nov 200427 Oct 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2248830A14 Nov 200410 Nov 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2279726A225 May 20062 Feb 2011Biorest Ltd.Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP2289567A215 Dec 20042 Mar 2011Regentis Biomaterials Ltd.Matrix comprising naturally-occurring crosslinked protein backbone
EP2292762A222 Dec 20039 Mar 2011Board of Regents, The University of Texas SystemVMP-like sequences of pathogenic Borrelia species and strains
EP2295973A12 Sep 200516 Mar 2011THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesCompositions and methods for the detection of HIV-1/HIV-2 infection.
EP2295974A12 Sep 200516 Mar 2011THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESCompositions and methods for the detection of HIV-1/HIV-2 infection
EP2295980A130 Oct 200316 Mar 2011Yissum Research Development Company, of The Hebrew University of JerusalemMolecules and methods using same for measuring non-transferrin bound iron
EP2301575A14 Nov 200430 Mar 2011Novartis Vaccines and Diagnostics, Inc.Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
EP2305794A126 Jan 20036 Apr 2011Gamida Cell Ltd.Expansion of renewable stem cell populations
EP2308994A121 Mar 200213 Apr 2011Yeda Research And Development Co., Ltd.Methods for determining a risk to develop cancer
EP2309269A12 Sep 200513 Apr 2011THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESCompositions and methods for the detection of HIV-1/HIV-2 infection.
EP2311938A14 Feb 200020 Apr 2011Pluristem Ltd.Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP2312315A118 May 200620 Apr 2011Novartis AGMethods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
EP2316441A116 Feb 20064 May 2011Hadasit Medical Research Services And DevelopmentBisphosphonates for treating endometriosis
EP2316950A119 Mar 20014 May 2011Technion Research and Development Foundation, Ltd.Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
EP2319857A24 Mar 200411 May 2011Yeda Research And Development Co., Ltd.Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
EP2322561A15 Oct 200418 May 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2329814A111 Feb 20038 Jun 2011Technion Research and Development Foundation, Ltd.Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer
EP2330132A14 Apr 20048 Jun 2011Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2336330A214 Jun 200522 Jun 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2338896A211 Dec 200329 Jun 2011R.B.T. (Rakuto Bio Technologies) Ltd.Use of lignin peroxidase in skin and hair lightening
EP2343373A114 Jun 200513 Jul 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2354164A15 Oct 200410 Aug 2011Yeda Research And Development Co., Ltd.Anti-NIK antibodies and uses thereof
EP2357478A230 Nov 200117 Aug 2011Crawford Healthcare Holdings LimitedDiagnosis of disease
EP2359853A17 Aug 200124 Aug 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2359854A17 Aug 200124 Aug 2011Technion Research and Development Foundation, Ltd.Pharmaceutical compositions and methods useful for modulating angiogenesis
EP2365087A220 May 200414 Sep 2011Evogene Ltd.Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
EP2366775A122 Mar 200721 Sep 2011Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2368569A218 Jan 200728 Sep 2011University Of ChicagoCompositions and methods related to staphylococcal bacterium proteins
EP2368570A218 Jan 200728 Sep 2011University Of ChicagoCompositions and methods related to staphylococcal bacterium proteins
EP2383345A120 Dec 20072 Nov 2011Evogene Ltd.Polynucleotides and polypeptides involved in plant fiber development and methods of using same
EP2390312A129 Nov 200630 Nov 2011Gamida Cell Ltd.Methods of improving stem cell homing and engraftment
EP2425841A122 Nov 20017 Mar 2012Vascular Biogenics Ltd.Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
EP2441840A118 Jul 200618 Apr 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2457999A27 Dec 200330 May 2012Technion Research & Development Foundation Ltd.Culture medium for pluropotent stem cells
EP2463382A17 Dec 201113 Jun 2012Enterologics, Inc.Method for identifying E. Coli M-17
EP2465920A225 Feb 201020 Jun 2012Tel HaShomer Medical Research Infrastructure and Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
EP2465924A218 Jun 200620 Jun 2012Ramot at Tel-Aviv University Ltd.Isolated cells and populations comprising same for the treament of cns diseases
EP2471807A15 Feb 20074 Jul 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2478924A131 Jan 200825 Jul 2012Technion Research & Development FoundationAlbumin fibers and fabrics and methods of generating and using same
EP2484768A218 Jul 20068 Aug 2012Protalix Ltd.Mucosal or enteral administration of biologically active macromolecules
EP2487182A29 Jul 200615 Aug 2012FULCRUM SP Ltd.SP1 polypeptides, modified SP1 polypeptides and uses thereof
EP2487187A23 Jan 200815 Aug 2012Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
EP2492279A125 Feb 201129 Aug 2012Laboratorios Del. Dr. Esteve, S.A.Rapid immunogen selection method using lentiviral display
EP2500428A210 Jul 200819 Sep 2012Yeda Research and Development Co. Ltd.Nucleic acid construct systems capable of diagnosing or treating a cell state
EP2508596A221 Feb 200310 Oct 2012Bayer HealthcareMN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
EP2514315A221 Aug 200624 Oct 2012Yeda Research and Development Co. Ltd.Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
EP2514766A227 Mar 200824 Oct 2012Technion Research & Development Foundation Ltd.Antibodies, methods and kits for diagnosing and treating melanoma
EP2522718A122 Feb 200814 Nov 2012Baylor Research InstituteTherapeutic applications of activation of human antigen-presenting cells through dectin-1
EP2526952A115 Jul 200428 Nov 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2526953A115 Jul 200428 Nov 2012Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2527363A11 Feb 200828 Nov 2012Baylor Research InstituteVaccines based on targeting antigen to dcir expressed on antigen-presenting cells
EP2527441A215 Jul 200828 Nov 2012Technion Research & Development FoundationCompositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
EP2529754A13 May 20085 Dec 2012Agency For Science, Technology And Research (A*star)Antibodies binding to an intracellular PRL-1 or PRL-3 polypeptide
EP2532674A15 Feb 200712 Dec 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2532675A15 Feb 200712 Dec 2012Modigene IncLong-acting polypeptides and methods of producing and administering same
EP2540301A215 Jul 20042 Jan 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2540302A115 Jul 20042 Jan 2013Bar-Ilan UniversityMethods and pharmaceutical compositions for healing wounds
EP2548951A122 Mar 200723 Jan 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2550982A126 Jul 201230 Jan 2013Technion Research & Development Foundation Ltd.Devices for surgical applications
EP2561889A231 Jul 200327 Feb 2013Yeda Research and Development Co. Ltd.Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
EP2581445A17 Aug 200817 Apr 2013Yeda Research And Development Co. Ltd.Regulators of MMP-9 and uses thereof
EP2591789A22 Sep 200815 May 2013Pluristem Ltd.Adherent cells from adipose or placenta tissues and use thereof in therapy
EP2599790A126 Nov 20085 Jun 2013Yissum Research Development Company of The Hebrew University of JerusalemCompositions comprising fibrous polypeptides and polysachharides
EP2620493A126 May 200931 Jul 2013Ramot at Tel Aviv University Ltd.Mesenchymal stem cells for the treatment of CNS diseases
EP2626417A122 Mar 200714 Aug 2013Pluristem Ltd.Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2633854A13 Dec 20094 Sep 2013Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating MND
EP2641606A126 May 200925 Sep 2013Pluristem Ltd.Methods of treating inflammatory colon diseases
EP2657342A110 Aug 200930 Oct 2013Genisphere Inc.DNA dendrimers protected against nuclease degradation are useful as vectors for the delivery of siRNA
EP2684889A231 Jan 200815 Jan 2014Baylor Research InstituteMultivariable antigens complexed with targeting humanized monoclonal antibody
EP2698377A117 Aug 201219 Feb 2014Laboratorios Del. Dr. Esteve, S.A.Enhanced rapid immunogen selection method for HIV gp120 variants
EP2716654A124 Oct 20069 Apr 2014Evogene Ltd.Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
EP2719394A129 Jun 200416 Apr 2014Tel Aviv University Future Technology Development L.P.Peptides antibodies directed thereagainst for diagnosing and treating amyloid-associated diseases
WO1980002747A1 *19 May 198011 Dec 1980Rapidex LtdUltrasensitive enzymatic radioimmunoassay method
WO1981002792A1 *20 Mar 19811 Oct 1981Res Triangle InstDetection of antibiotics in milk
WO1982002601A1 *13 Jan 19825 Aug 1982American Hospital Supply CorpSolid phase system for ligand assay
WO1983000877A1 *12 Aug 198217 Mar 1983Icl ScientGlucose oxidase immunohistochemical detection of antinuclear antibodies
WO1985002260A1 *8 Nov 198323 May 1985QuidelRapid plunger immunoassay method and apparatus
WO1985003950A1 *6 Mar 198512 Sep 1985Scripps Clinic ResA sv40 expression vector containing hbxag as an expression marker
WO1985004397A119 Mar 198510 Oct 1985OncogenPlatelet related growth regulator
WO1986004421A1 *17 Jan 198531 Jul 1986Hygeia Sciences Limited PartneEnzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
WO1997005886A1 *5 Aug 199620 Feb 1997Univ TexasCompositions for conferring immunogenicity to a peptide
WO2002044736A230 Nov 20016 Jun 2002Molecular Skincare LtdDiagnosis and treatment of epidermal or skin diseases
WO2003046201A21 Oct 20025 Jun 2003Kimberly Clark CoDetection and identification of enteric bacteria
WO2004018698A220 Aug 20034 Mar 2004Genitrix LlcLectin compositions and methods for modulating an immune response to an antigen
WO2004060135A231 Dec 200322 Jul 2004Andrew P LevyMethods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
WO2005033142A25 Oct 200414 Apr 2005Yeda Res & DevAnti-nik antibodies and uses thereof
WO2005033145A15 Oct 200414 Apr 2005Yeda Res & DevAntibodies to nik, their preparation and use
WO2005051423A230 Nov 20049 Jun 2005Yeda Res & DevMethods and agents for immune modulation and methods for identifying immune modulators
WO2006134602A218 Jun 200621 Dec 2006Univ RamotIsolated cells and populations comprising same for the treatment of cns diseases
WO2007023491A221 Aug 20061 Mar 2007Yeda Res & DevUniversal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007031996A111 Sep 200622 Mar 2007Rappaport Family Inst For ResCompositions and methods for diagnosing and treating an inflammation
WO2007034487A121 Sep 200629 Mar 2007Yissum Res Dev CoNucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2007091254A16 Feb 200716 Aug 2007Rappaport Family Inst For ResMethods and kit for diagnosing t1dm
WO2007094985A25 Feb 200723 Aug 2007Modigene IncLong-acting polypeptides and methods of producing and administering same
WO2007110869A228 Mar 20074 Oct 2007Tel Hashomer Medical Res InfraMethods and kits for determining predisposition to warfarin resistance
WO2007124299A217 Apr 20071 Nov 2007Novartis AgAntagonist anti-cd40 antibody pharmaceutical compositions
WO2008041183A22 Oct 200710 Apr 2008Technion Res & Dev FoundationMicrotubes and methods of producing same
WO2008084410A23 Jan 200817 Jul 2008Humabs LlcHuman cytomegalovirus neutralising antibodies and use thereof
WO2008093341A231 Jan 20087 Aug 2008Technion Res & Dev FoundationElectrospun scaffolds and methods of generating and using same
WO2008093342A231 Jan 20087 Aug 2008Technion Res & Dev FoundationAlbumin fibers and fabrics and methods of generating and using same
WO2008097870A22 Feb 200814 Aug 2008Baylor Res InstAgents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc- asgpr)
WO2008120202A227 Mar 20089 Oct 2008Technion Res & Dev FoundationAntibodies, methods and kits for diagnosing and treating melanoma
WO2008120216A12 Apr 20089 Oct 2008Univ RamotMethods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease
WO2009010968A215 Jul 200822 Jan 2009Yitzchak HillmanDisease treatment via antimicrobial peptides or their inhibitors
WO2009083958A223 Dec 20089 Jul 2009Evogene LtdIsolated polypeptides, polynucleotides useful for modifying water user efficiency, fertilizer use efficiency, biotic/abiotic stress tolerance, yield and biomass in plants
WO2009104174A212 Feb 200927 Aug 2009Technion Research & Development Foundation Ltd .A method of attaching a cell-of-interest to a microtube
WO2010017544A210 Aug 200911 Feb 2010Genisphere, Inc.Long-acting dna dendrimers and methods thereof
WO2010029545A210 Sep 200918 Mar 2010Ben Gurion University Of The Negev Research And Development AuthorityCompositions and methods for treating s. pneumoniae infection
WO2010042481A16 Oct 200915 Apr 2010University Of ChicagoCompositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2010055525A117 Nov 200920 May 2010Technion Research & Development Foundation Ltd.Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A117 Nov 200927 May 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A124 Nov 20093 Jun 2010Biodalia Microbiological Technologies Ltd.A method of in-situ enrichment of foods with fructan
WO2010064231A129 Nov 200910 Jun 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A13 Dec 200910 Jun 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods and kits for determining predisposition to cancer
WO2010071610A121 Dec 200924 Jun 2010Agency For Science, Technology And Research (A*Star)Severe chikungunya biomarkers
WO2010076642A128 Dec 20098 Jul 2010Tel Hashomer Medical Research, Infrastructure And Services LtdPeptides and compositions for prevention of cell adhesion and methods of using same
WO2010076788A229 Dec 20098 Jul 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A130 Dec 20098 Jul 2010Technion Research & Development Foundation Ltd.Method of denitrifying brine and systems capable of same
WO2010086856A231 Jan 20105 Aug 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
WO2010086867A22 Feb 20105 Aug 2010Ramot At Tel Aviv University Ltd.Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A14 Feb 201012 Aug 2010Yeda Research And Development Co. Ltd.Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
WO2010097793A225 Feb 20102 Sep 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of renal stem cells and methods of isolating and using same
WO2010097794A125 Feb 20102 Sep 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of reprogramming renal cells
WO2010103517A110 Mar 201016 Sep 2010Rappaport Family Institute For Research In The Medical SciencesSoluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A128 Mar 20107 Oct 2010Tel Hashomer Medical Research Infrastructure And Services Ltd.Methods of predicting clinical course and treating multiple sclerosis
WO2010113146A128 Feb 20107 Oct 2010The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical CenterA method of regulating proliferation and differentiation of keratinocyes
WO2010116375A18 Apr 201014 Oct 2010Yeda Research And Development Co. Ltd.Isolated peptides for regulating apoptosis
WO2010135663A221 May 201025 Nov 2010The United States Of America , As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods for the detection of hiv-1/hiv-2 infection
WO2010137013A125 May 20102 Dec 2010Ramot At Tel Aviv University Ltd.Crystallized photosystem i units from the pea plant and their use in solid state devices
WO2010137017A226 May 20102 Dec 2010Yeda Research And Development Co. Ltd.Proteasome inhibitors and uses thereof
WO2010137020A127 May 20102 Dec 2010Yeda Research And Development Co. Ltd.Methods of treating inflammation
WO2010137021A227 May 20102 Dec 2010Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of generating connective tissue
WO2010150259A124 Jun 201029 Dec 2010Fund For Medical Research Development Of Infrastructure And Health Services -Rambam Medical CenterMethods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
WO2011004379A18 Jul 201013 Jan 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Compositions and methods for treating cancer
WO2011010309A121 Jul 201027 Jan 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.A method of diagnosing cancer
WO2011013130A229 Jul 20103 Feb 2011Ramot At Tel-Aviv University Ltd.Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021171A122 Aug 201024 Feb 2011Beeologics, LlcPreventing and curing beneficial insect diseases via plant transcribed molecules
WO2011021194A217 Aug 201024 Feb 2011Technion Research & Development Foundation Ltd.Pericyte progenitor cells and methods of generating and using same
WO2011024172A226 Aug 20103 Mar 2011Technion Research & Development Foundation Ltd.Liposomal compositions and uses of same
WO2011030329A131 Aug 201017 Mar 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating tumors
WO2011030332A25 Sep 201017 Mar 2011Yeda Research And Development Co. Ltd.Methods for hematopoietic precursor mobilization
WO2011030336A16 Sep 201017 Mar 2011Ramot At Tel-Aviv University Ltd.Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011033506A215 Sep 201024 Mar 2011Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2011033511A116 Sep 201024 Mar 2011Ramot At Tel-Aviv University Ltd.Peptides for the treatment of oxidative stress related disorders
WO2011045796A114 Oct 201021 Apr 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2011048600A121 Oct 201028 Apr 2011Danziger Innovations Ltd.Generating genotypic variations in plant genomes by gamete infection
WO2011055366A18 Nov 201012 May 2011Medical Research & Development Fund For Health Services Bnai Zion Medical Center, The State Of IsraelMo-1 conditional knock-out non-human animal and uses thereof
WO2011058555A111 Nov 201019 May 2011Yeda Research And Development Co. Ltd.A method of editing dna in a cell and constructs capable of same
WO2011058557A111 Nov 201019 May 2011Ramot At Tel-Aviv University Ltd.Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011061736A117 Nov 201026 May 2011Protalix Ltd.Alkaline alpha galactosidase for the treatment of fabry disease
WO2011063198A219 Nov 201026 May 2011St. Jude Children's Research HospitalMethods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011064669A229 Nov 20103 Jun 2011Pluristem Ltd.Adherent cells from placenta and use of same in disease treatment
WO2011064773A124 Nov 20103 Jun 2011Collplant Ltd.Method of generating collagen fibers
WO2011067745A26 Dec 20109 Jun 2011Rosetta Green Ltd.Compositions and methods for enhancing plants resistance to abiotic stress
WO2011072091A19 Dec 201016 Jun 2011Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the cns
WO2011080740A129 Dec 20107 Jul 2011Gamida-Cell Ltd.Methods for enhancing natural killer cell proliferation and activity
WO2011086509A112 Jan 201121 Jul 2011Vascular Biogenics Ltd.Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011092700A127 Jan 20114 Aug 2011Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011099006A210 Feb 201118 Aug 2011Yeda Research And Development Co. Ltd.Enzymatic systems for carbon fixation and methods of generating same
WO2011107939A11 Mar 20119 Sep 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A13 Mar 20119 Sep 2011Yeda Research And Development Co. Ltd.Methods of measuring protein stability
WO2011111034A125 Jan 201115 Sep 2011Yeda Research And Development Co. Ltd.Recombinant protein production in heterologous systems
WO2011111050A210 Mar 201115 Sep 2011Jacob EdreiMethods of generating hydrogen
WO2011125015A24 Apr 201113 Oct 2011Bar-Ilan UniversityProtease-activatable pore-forming polypeptides
WO2011128897A112 Apr 201120 Oct 2011Technion Research & Development Foundation Ltd.Populations of pancreatic progenitor cells and methods of isolating and using same
WO2011132182A122 Mar 201127 Oct 2011Yeda Research And Development Co. Ltd.MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011138778A24 May 201110 Nov 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of identifying inhibitors of polypeptides-of-interest
WO2011138785A25 May 201110 Nov 2011Rappaport Family Institute For Research In The Medical SciencesUse of ccl1 in therapy
WO2011141914A112 May 201117 Nov 2011Tel Hashomer Medical Research Infrastructure And Services Ltd.Isolated populations of adult renal cells and methods of isolating and using same
WO2011151833A12 Jun 20118 Dec 2011Ramot At Tel-Aviv University Ltd.Methods of treating diabetes and compositions capable of same
WO2011154940A16 Jun 201115 Dec 2011Osnat Ashur-FabianMethods and kits for diagnosing conditions related to hypoxia
WO2011158242A216 Jun 201122 Dec 2011Futuragene Israel Ltd.Pest -resistant plants containing a combination of a spider toxin and a chitinase
WO2011158243A216 Jun 201122 Dec 2011Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of diagnosing and treating cancer
WO2012007919A214 Jul 201119 Jan 2012Technion Research & Development Foundation Ltd.Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2012007950A214 Jul 201119 Jan 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012007951A114 Jul 201119 Jan 2012Technion Research & Development Foundation Ltd.Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012011113A221 Jul 201126 Jan 2012Shai YarkoniRegulatory immune cells with enhanced targeted cell death effect
WO2012014205A127 Jul 20112 Feb 2012Technion Research & Development Foundation Ltd.Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012014207A227 Jul 20112 Feb 2012Technion Research & Development Foundation Ltd.Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A227 Jul 20112 Feb 2012Yeda Research And Development Co. Ltd.Methods and systems for assessing clonality of cell cultures
WO2012017439A24 Aug 20119 Feb 2012Ramot At Tel-Aviv University Ltd.Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012025914A17 Jul 20111 Mar 2012Ramot At Tel-Aviv University Ltd.Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A124 Aug 20111 Mar 2012Fund For Medical Research Development Of Infrastructure And Health Services - At Rambam Medical CenterMethods of improving transplantation using sdf-1alpha
WO2012032510A16 Sep 201115 Mar 2012Yeda Research And Development Co. Ltd.Primers for amplifying dna and methods of selecting same
WO2012032519A27 Sep 201115 Mar 2012Hadasit Medical Research Services And Development Ltd.Methods of diagnosing parkinson's disease
WO2012032520A17 Sep 201115 Mar 2012Protalix Ltd.Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032521A27 Sep 201115 Mar 2012Technion Research & Development Foundation Ltd.Novel methods and culture media for culturing pluripotent stem cells
WO2012032525A28 Sep 201115 Mar 2012Yeda Research And Development Co. Ltd.An immunosuppressive drug combination for a stable and long term engraftment
WO2012032526A28 Sep 201115 Mar 2012Yeda Research And Development Co. Ltd.Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
WO2012034067A19 Sep 201115 Mar 2012The University Of ChicagoMethods and compositions involving protective staphylococcal antigens
WO2012035539A115 Sep 201122 Mar 2012Ramot At Tel-Aviv University Ltd.Methods of expanding and redifferentiating islet beta cells
WO2012038956A120 Sep 201129 Mar 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Method of treating neurodegenerative diseases
WO2012052872A210 Oct 201126 Apr 2012Yeda Research And Development Co. Ltd.Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A112 Oct 201126 Apr 2012Vascular Biogenics Ltd.Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
WO2012056452A227 Oct 20113 May 2012Nanocyte (Israel) Ltd.Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
WO2012056455A127 Oct 20113 May 2012Yeda Research And Development Co. Ltd.Methods of generating antibodies to metalloenzymes
WO2012059922A23 Nov 201110 May 2012Futuragene Israel Ltd.Transgenic plants with improved saccharification yields and methods of generating same
WO2012075111A130 Nov 20117 Jun 2012Novartis AgUses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012090205A228 Dec 20115 Jul 2012Bio-Fd&C Co. Ltd.Plant extracts for the treatment and prevention of infections
WO2012098537A17 Sep 201126 Jul 2012Protalix Ltd.Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2012104851A131 Jan 20129 Aug 2012Yeda Research And Development Co. Ltd.Methods of diagnosing disease using overlap extension pcr
WO2012113921A124 Feb 201230 Aug 2012Fundació Privada Institut De Recerca De La Sida - CaixaRapid selection method for hiv gp-120 variants
WO2012114339A123 Feb 201230 Aug 2012Rappaport Family Institute For Research In The Medical SciencesHigh affinity molecules capable of binding a type a plexin receptor and uses of same
WO2012117373A11 Mar 20127 Sep 2012Ramot At Tel-Aviv University Ltd.Genetically modified muscle cells which express neurotrophic factors
WO2012117406A21 Mar 20127 Sep 2012Futuragene Israel Ltd.Bacterial resistant transgenic plants
WO2012120500A25 Mar 201213 Sep 2012BAR-SHIMON, MeiravLow fucose cell lines and uses thereof
WO2012120518A18 Mar 201213 Sep 2012Ramot At Tel-Aviv University Ltd.Compositions and methods for diagnosing and treating phenylketonuria (pku)
WO2012123938A126 Feb 201220 Sep 2012Tel Hashomer Medical Research Infrastructure And Services Ltd.Quinolone analogs for treating autoimmune diseases
WO2012123949A115 Mar 201220 Sep 2012Ramot At Tel-Aviv University Ltd.Bi- and monospecific, asymmetric antibodies and methods of generating the same
WO2012127320A122 Mar 201227 Sep 2012Pluristem Ltd.Methods for treating radiation or chemical injury
WO2012127475A122 Mar 201227 Sep 2012Neurim Pharmaceuticals (1991) Ltd.Neuroprotective peptides
WO2012131680A228 Mar 20124 Oct 2012Yeda Research And Development Co. Ltd.Compositions and methods for treating inflammation
WO2012137202A13 Apr 201211 Oct 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
WO2012137207A14 Apr 201211 Oct 2012Ramot At Tel-Aviv University Ltd.Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2012140519A215 Apr 201218 Oct 2012Pluristem Ltd.Methods and systems for harvesting cells
WO2012150600A23 May 20128 Nov 2012Ramot At Tel-Aviv University Ltd.Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A19 May 201215 Nov 2012Hadasit Medical Research Services And Development Ltd.Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A210 May 201215 Nov 2012Rakuto Bio Technologies Ltd.Methods and device for lightening skin complexion
WO2012156976A116 May 201222 Nov 2012Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A223 May 201229 Nov 2012Ofir MenasheFormulations of microorganism comprising particles and uses of same
WO2012164380A231 May 20126 Dec 2012Hutchison Biofilm Medical Solutions LimitedDispersion and detachment of cell aggregates
WO2012164565A131 May 20126 Dec 2012Yeda Research And Development Co. Ltd.Compositions and methods for downregulating prokaryotic genes
WO2012176203A119 Jun 201227 Dec 2012Kaiima Bio Agritech Ltd.Common wheat, plants or parts thereof having partially or fully multiplied genome, hybrids and products thereof and methods of generating and using same
WO2013011347A118 Jul 201124 Jan 2013Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
WO2013011507A117 Jul 201224 Jan 2013Kaiima Bio Agritech Ltd.Maize plants having a partially or fully multiplied genome and uses thereof
WO2013018060A22 Aug 20127 Feb 2013Yeda Research And Development Co. Ltd.Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A29 Aug 201214 Feb 2013Yeda Research And Development Co.Ltd.Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
WO2013024481A113 Aug 201221 Feb 2013Kaiima Bio Agritech Ltd.Durum wheat plants having a partially or fully multiplied genome and uses thereof
WO2013035099A16 Sep 201214 Mar 2013Yeda Research And Development Co. Ltd.Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
WO2013061328A225 Oct 20122 May 2013Yeda Research And Development Co. Ltd.Method of treating cancer
WO2013067076A21 Nov 201210 May 2013Quark Pharmaceuticals, Inc.Methods and compositions for neuroprotection
WO2013070821A18 Nov 201216 May 2013Quark Pharmaceuticals, Inc.Methods and compositions for treating diseases, disorders or injury of the nervous system
WO2013076729A122 Nov 201230 May 2013Danziger Dan Flower FarmOtomeria plants
WO2013076730A127 Nov 201230 May 2013Yeda Research And Development Co. Ltd.Methods of regulating angiogenesis and compositions capable of same
WO2013084190A16 Dec 201213 Jun 2013Yeda Research And Development Co. Ltd.Mammalian fetal pulmonary cells and therapeutic use of same
WO2013093921A120 Dec 201227 Jun 2013Collplant Ltd.Collagen coated synthetic polymer fibers
WO2013098813A131 Dec 20124 Jul 2013Qbi Enterprises Ltd.Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
WO2013098820A126 Dec 20124 Jul 2013Kaiima Bio Agritech Ltd.Cultivated sorghum plant having a partially or fully multiplied genome and uses of same
WO2013114363A230 Jan 20138 Aug 2013Yeda Research And Development Co.Ltd.Antimicrobial agents
WO2013114373A131 Jan 20138 Aug 2013Protalix Ltd.Inhalable liquid formulations of dnase i
WO2013114374A131 Jan 20138 Aug 2013Protalix Ltd.Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
WO2013121405A119 Feb 201322 Aug 2013Protalix Ltd.Oral unit dosage forms and uses of same for the treatment of gaucher disease
WO2013121426A113 Feb 201322 Aug 2013Gamida-Cell Ltd.Culturing of mesenchymal stem cells
WO2013121427A113 Feb 201322 Aug 2013Gamida-Cell Ltd.Mesenchymal stem cells conditioned medium and methods of generating and using the same
WO2013124816A221 Feb 201329 Aug 2013Brainstem Biotec Ltd.Generation of neural stem cells and motor neurons
WO2013124817A221 Feb 201329 Aug 2013Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
WO2013128454A128 Feb 20136 Sep 2013The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani CenterMale sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A17 Mar 201312 Sep 2013Yeda Research And Development Co. Ltd.Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013136335A114 Mar 201319 Sep 2013Yeda Research And Development Co. Ltd.Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
WO2013140247A114 Mar 201326 Sep 2013Humabs Biomed SaAntibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013153553A211 Apr 201317 Oct 2013Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.Compositions for controlling varroa mites in bees
WO2013160895A124 Apr 201331 Oct 2013Biokine Therapeutics Ltd.Peptides and use thereof in the treatment of large cell lung cancer
WO2013168164A19 May 201314 Nov 2013Yeda Research And Development Co. Ltd.Variants of tace pro-domain as tnf-a inhibitor and their medical use
WO2013183048A13 Jun 201312 Dec 2013Ben-Gurion University Of The Negev Research And Development AuthorityFunctionalized titanium binding peptides and implants coated with same
WO2014006621A13 Jul 20139 Jan 2014Nanospun Technologies Ltd.Methods and devices for adsorption and biodegradation of petroleum
WO2014020599A129 Jul 20136 Feb 2014Yeda Research And Development Co. Ltd.Use of the reductive glycine pathway for generating formatotrophic and autotrophic microorganisms
WO2014020608A131 Jul 20136 Feb 2014Yeda Research And Development Co. Ltd.Methods of diagnosing and treating motor neuron diseases
WO2014024183A14 Aug 201313 Feb 2014Brainstorm Cell Therapeutics Ltd.Methods of generating mesenchymal stem cells which secrete neurotrophic factors
WO2014027082A116 Aug 201320 Feb 2014Laboratorios Del Dr. Esteve, S.A.Enhanced rapid immunogen selection method for hiv gp120 variants
WO2014033723A13 Sep 20136 Mar 2014A.B. Seeds Ltd.Method of improving abiotic stress tolerance of plants and plants generated thereby
WO2014041544A112 Sep 201320 Mar 2014Ramot At Tel-Aviv University Ltd.Immunoparticles and methods of generating and using same
WO2014052588A126 Sep 20133 Apr 2014Research Development FoundationAttenuated chikungunya virus
WO2014068553A127 Oct 20138 May 2014Yeda Research And Development Co. Ltd.Aptamers, multimeric aptamers and uses thereof
WO2014083567A228 Nov 20135 Jun 2014Yeda Research And Development Co. Ltd.Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
WO2014106837A230 Dec 201310 Jul 2014A. B. Seeds Ltd.ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
WO2014106838A230 Dec 201310 Jul 2014A.B. Seeds Ltd.Methods of introducing dsrna to plant seeds for modulating gene expression
WO2014108850A29 Jan 201417 Jul 2014Yeda Research And Development Co. Ltd.High throughput transcriptome analysis
Classifications
U.S. Classification435/7.8, 435/188, 436/530, 436/518, 436/818, 436/533, 436/808, 435/13, 435/25, 435/7.94, 435/971, 435/7.92
International ClassificationG01N33/541, G01N33/543, G01N33/74
Cooperative ClassificationY10S436/808, Y10S436/818, Y10S435/971, G01N33/743, G01N33/541, G01N33/54306
European ClassificationG01N33/74B, G01N33/543B, G01N33/541